Apogee Therapeutics (APGE) Operating Leases (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Operating Leases data on file, last reported at $4.9 million in Q1 2026.

• Quarterly Operating Leases fell 37.39% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 37.39% YoY) and the FY2025 annual result came in at $5.3 million, down 37.83% from the prior year.
• Operating Leases declined to $4.9 million in Q1 2026 per APGE's latest filing, from $5.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $9.3 million in Q3 2024 and bottomed at $630000.0 in Q1 2024.
• The 4-year median for Operating Leases is $5.6 million (2025), against an average of $5.4 million.
• Peak annual rise in Operating Leases reached 1144.44% in 2025, while the deepest fall reached 37.91% in 2025.
• Tracing APGE's Operating Leases over 4 years: stood at $933000.0 in 2023, then surged by 821.44% to $8.6 million in 2024, then sank by 37.83% to $5.3 million in 2025, then fell by 8.16% to $4.9 million in 2026.
• Per Business Quant, the three latest APGE Operating Leases figures stand at $4.9 million (Q1 2026), $5.3 million (Q4 2025), and $5.8 million (Q3 2025).

Peer Comparison